AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Management of the autoimmune disease myasthenia gravis in pregnant women is most successful with a team approach to care.
Myasthenia gravis (MG), a neuromuscular disorder, frequently affects reproductive-age women. "The treatment of MG in women therefore poses unique and challenging issues to neurologists, obstetricians, and neonatologists as the safety of both mother and fetus needs to be carefully considered when choosing a therapeutic plan," stated E. Ciafaloni and colleagues, University of Rochester.
"The severity of generalized weakness and the potential for respiratory insufficiency and myasthenic crises in the mother should dictate how aggressive a treatment plan should be," they wrote in a recent issue of Seminars in Neurology.
"The potential effects of immunosuppressant medications on the fetus should always be weighed against the risk of myasthenic crises and its potential to endanger both mother and fetus.
"Successful management of MG during pregnancy and in the postpartum period is possible in many cases but requires ...